INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
INmune Bio reported statistically significant treatment effects on white matter MRI biomarkers in its Phase 2 MINDFuL Alzheimer's trial for XPro1595. The full intent-to-treat population (n=200) showed a p-value of 0.0028 and a medium effect size (d=0.46), while the inflammation-enriched subgroup (n=100) showed a stronger effect (p=0.0098, d=0.59).
Key figures
- Drug Name
- XPro1595
- Phase Of Trial
- Phase 2
- N full population
- 200
- N enriched population
- 100
- P value full population
- 0.0028
- Effect size full population
- 0.46
- P value enriched population
- 0.0098
- Effect size enriched population
- 0.59
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.